The Sources Portal
       Sources Directory     A to Z Index     Topic Index News Releases     RSS Sources Select News RSS Feed     Sources Calendar      

For Journalists
& News Media

SOURCES - Experts & media spokespersons News Releases Event Calendar Fame & Fortune
Awards & Prizes More Resources

Media Relations
& Publicity

Include yourself
in SOURCES FAQ Membership Form Be an Affiliate Sources Shop Media Directory
 Government Directory
 Subscriptions How to distribute
your media releases Submit a news release or Calendar event Services Overview

More Resources

Media Names & Numbers
Canada’s print and broadcast media Parliamentary Names & Numbers
Canada's federal and provincial governments Universities & Colleges Speakers Authors Sources Bookshelf Sources Select Resources Sources for Students Links & Resources Twitter Media Blogs Complete Topic Index Topics by Category Índice temático Download PDFs

Contact

Contact Jobs & Internships

Dr. Cameron Durrant, MD, MBA, Alzheimer

Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biotech Expert


Cameron Durrant, MD, MBA, is the Executive Chairman of the Board of Anavex Life Sciences Corp. ("ANAVEX") (AVXL:OB), a biopharmaceutical company engaged in the discovery and development of novel drug candidates for the treatment of neurological diseases (Alzheimer's disease, epilepsy and pain) and various types of cancer. The company has developed a rich portfolio of drug candidates using its proprietary drug discovery SIGMACEPTOR™ platform and is preparing to enter Phase 1 clinical trials with its lead candidate for the treatment of Alzheimer's in 2010.

Dr. Durrant has a unique entrepreneurial background coupled with almost 20 years of international pharmaceutical and biotech experience. He has held executive positions at both specialty and major global pharmaceutical companies, including Merck & Co., GlaxoSmithKline, Pharmacia Corporation (now part of Pfizer, Inc.) and Johnson & Johnson. He is a serial entrepreneur and CEO.

Dr. Durrant is an experienced media guest (radio, print, online and industry press). He can discuss all aspects of the drug development-commercialization-value creation process (both clinical trials and business considerations), particularly in relation to Alzheimer's disease, other neurological diseases, cancer and infectious diseases. He is highly skilled at making technical topics easy to understand for a general audience.

Website: www.anavex.com
Toll free: 1-866-505-2895
E-mail: ir@anavex.com

Media Inquiries:
Primoris Group - Media Relations
Toll free: 1-866-505-2895
E-mail: media@primorisgroup.com

News Releases

Areas of Expertise:




    Information and Media Resources from Sources
Sources Directory The directory of experts, contacts and media spokespersons.
Find how to include yourself in Sources.
Sources Calendar Check out newsworthy events from across Canada.
News Releases Media releases from clients of the Sources media relations service.
Media Names & Numbers Directory of Canada's print and broadcast media.
Parliamentary Names & Numbers Full contact information for government, political parties, lobbyists, and embassies.
Sources is an online portal and directory for journalists, writers, news editors, researchers. Use Sources to find experts, media contacts, spokespersons, scientists, lobbyists, officials, speakers, university professors, researchers, newsmakers, CEOs, executive directors, media relations contacts, spokespeople, talk show guests, PR representatives, Canadian sources, story ideas, research studies, databases, universities, colleges, associations, businesses, government, research institutions, lobby groups, non-government organizations (NGOs), in Canada and internationally.
© Sources 2010. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.